Lipid peroxidation in Alzheimer's Disease: Emphasis on metal-mediated neurotoxicity

Acta Neurologica Scandinavica

Volumn 124, Issue 5, 2011, Pages 295-301

  Obulesu, M ^a   Venu, R ^a   Somashekhar, R ^a  

^a Capital College   (India)

Author keywords

Alzheimer's Disease; Lipid peroxidation; Metals; Neuroprotection; Oxidative stress; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANGELICA SINENSIS EXTRACT; ANTIOXIDANT; CLIOQUINOL; COPPER; GINSENOSIDE RG 1; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; METAL; NAPROXEN; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NUCLEOPHILE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RNA; SUPEROXIDE DISMUTASE; VALDECOXIB; ZINC;

ALZHEIMER DISEASE; APOPTOSIS; BODY WEIGHT; CELL AGING; CELL DEATH; CELL FUNCTION; CELL VIABILITY; DNA DAMAGE; DNA REPAIR; ELECTRON TRANSPORT; FENTON REACTION; GLYCATION; HOMEOSTASIS; IRON TRANSPORT; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MYELINATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NITRATION; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN CROSS LINKING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; LIPID PEROXIDATION; METALS; NEUROTOXINS; OXIDATIVE STRESS;

EID: 80052920480     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01483.x     Document Type: Review

References (80)

1. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-6.
2. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 2007;85:3036-40.
3. Bales KR. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology 2010;59:295-302.
4. Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA, Perry G. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol 2010;610:419-34.
5. Obulesu M, Rao DM. DNA damage and impairment of DNA repair in Alzheimer's Disease. Int J Neurosci 2010;120:397-403.
6. Obulesu M, Rao DM. Animal models of Alzheimer's Disease: an understanding of pathology and therapeutic avenues. Int J Neurosci 2010;120:531-7.
7. Obulesu M, Rao DM, Shamasundar NM. Studies on genomic DNA stability in aluminium maltolate treated aged New Zealand rabbit: relevance to the Alzheimer's animal model. J Clin Med Res 2009;1:212-8.
8. Dai X, Sun Y, Jiang Z. Protective effects of vitamin E against oxidative damage induced by Abeta1-40Cu(II) complexes. Acta Biochim Biophys Sin (Shanghai) 2007;39:123-30.
9. Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000;7:630S-6S.
10. Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita 2005;41:143-64.
11. Sayre LM, Perry G, Smith MA. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 1999;3:220-5.
12. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51:1143-8.
13. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol Biol 2000;46:731-41.
14. Zheng H, Blat D, Fridkin M. Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases. J Neural Transm Suppl 2006;71:163-72.
15. Sayre LM, Perry G, Harris PL, Schubert KA, Liu Y, Kathryn A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-9.
16. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: a cause for concern in the elderly? Curr Opin Clin Nutr Metab Care 2009;12:22-9.
17. Brass SD, Chen NK, Mulkern RV, Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006;17:31-40.
18. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redoxgenerated free radicals. Proc Natl Acad Sci USA 1997;94:9866-8.
19. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
20. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-14.
21. 2 catalytically but quench hydroxyl radicals. Biochemistry 2008;47:11653-64.
22. Hayashi T, Shishido N, Nakayama K et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 2007;43:1552-9.
23. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68:2092-7.
24. Huang X, Cuajungco MP, Atwood CS et al. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274:37111-6.
25. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000;1502:139-44.
26. Curtain CC, Ali F, Volitakis I et al. Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001;276:20466-73.
27. Dai XL, Sun YX, Jiang ZF. Cu(II) potentiation of Alzheimer Aβ1-40 cytotoxicity and transition on its secondary structure. Acta Biochim Biophys Sin 2006;38:765-72.
28. Munoz FJ, Opazo C, Gil-Gomez G et al. Vitamin E not 17 estradiol protects against vascular toxicity induced by amyloid wild type and the dutch amyloid variant. J Neurosci 2002;22:3081-9.
29. Brawer JR, Stein R, Small L, Cisse S, Schipper HM. Composition of Gomori-positive inclusions in astrocytes of the hypothalamic arcuate nucleus. Anat Rec 1994;240:407-15.
30. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998;152:188-96.
31. ε-(Carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001;31:175-80.
32. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.
33. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979;59:527-605.
34. Martin HJ, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009;178:145-50.
35. Atamna H, Frey WH. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 2007;7:297-310.
36. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Nat Acad Sci USA 2009;106:14670-5.
37. + anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 2008;13:173-84.
38. Ferrera P, Mercado-Gomez O, Silva-Aguilar M, Valverde M, Arias C. Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem Res 2008;33:1509-17.
39. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxid Redox Signal 2006;8:2039-45.
40. Liu ZZ, Ji BS. The protective effect of trihexyphenidyl on the beta-amyloid peptide (25-35)-induced cytotoxicity in PC12 cells. Clin Exp Med 2010;10:237-43.
41. + anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Life Sci 2008;83:96-102.
42. Huang SH, Lin CM, Chiang BH. Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress. Phytomedicine 2008;15:710-21.
43. Pensalfini A, Cecchi C, Zampagni M et al. Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Free Radic Biol Med 2008;144:1624-36.
44. Jesudason EP, Masilamoni JG, Ashok BS et al. Inhibitory effects of short-term administration of DL-alpha-lipoic acid on oxidative vulnerability induced by Abeta amyloid fibrils (25-35) in mice. Mol Cell Biochem 2008;11:145-56.
45. Eliuk SM, Renfrow MB, Shonsey EM, Barnes S, Kim H. Active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chem Res Toxicol 2007;20:1260-8.
46. Dmitriev LF. Shortage of lipid-radical cycles in membranes as a possible prime cause of energetic failure in aging and Alzheimer disease. Neurochem Res 2007;32:1278-91.
47. Jaffrey SR, Snyder SH. Nitric oxide: a neural messenger. Annu Rev Cell Dev Biol 1995;11:417-40.
48. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-8.
49. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
50. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988;18:1587-92.
51. Dawson TM, Dawson VL, Snyder SH. Nitric oxide as a mediator of neurotoxicity. NIDA Res Monogr 1993;136:258-71.
52. Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res 1998;118:215-29.
53. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal 2003;5:319-35.
54. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002;110:49-58.
55. Vodovotz Y, Lucia MS, Flanders KC et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184:1425-33.
56. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
57. Murad F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Prog Horm Res 1998;53:43-59.
58. Endoh M, Maiese K, Wagner J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 1994;651:92-100.
59. Satake K, Matsuyama Y, Kamiya M et al. Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury. Brain Res Mol Brain Res 2000;85:114-22.
60. Wada K, Chatzipanteli K, Busto R, Dietrich WD. Role of nitric oxide in traumatic brain injury in the rat. J Neurosurg 1998;89:807-18.
61. Kochman A, Koska C, Metodiewa D. Submolecular adventures of brain tyrosine: what are we searching for now? Amino Acids 2002;23:95-101.
62. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
63. Bolanos JP, Almeida A, Stewart V et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997;68:2227-40.
64. Pannu R, Singh I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 2006;49:170-82.
65. Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta 1999;1411:217-30.
66. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;34:879-86.
67. Popp R, Fleming I, Busse R. Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor: a modulator of arterial compliance. Circ Res 1998;82:696-703.
68. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-58.
69. Satoh K, Kawakami A, Shirabe S et al. Anti-cyclic citrullinated peptide antibody (anti-CCP antibody) is present in the sera of patients with dementia of Alzheimer's type in Asian. Acta Neurol Scand 2010;121:338-41.
70. Pablo J, Banack SA, Cox PA et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand 2009;120:216-25.
71. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931-6.
72. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
73. Wang YH, Du GH. Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res 2009;11:604-12.
74. Leeuwenburgh C, Hansen P, Shaish A, Holloszy JO, Heinecke JW. Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. Am J Physiol 1998;274:R453-61.
75. Matthews RT, Beal MF. Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Brain Res 1996;718:181-4.
76. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
77. Kumar A, Seghal N, Padi SV, Naidu PS. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacol 2006;551:58-66.
78. Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43-55.
79. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009;16:763-74.
80. Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-8.